Karine Rossignol
CEO
SI
Smart Immune
InactiveThe startup operates a thymus-empowered T-cell therapy platform that utilizes T cell progenitors to facilitate rapid immune recovery post-transplantation. This approach targets hematological malignancies and primary immune deficiencies by providing a polyclonal and safe immune response, enhanced through gene therapy and targeted conditioning.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$66.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup operates a thymus-empowered T-cell therapy platform that utilizes T cell progenitors to facilitate rapid immune recovery post-transplantation. This approach targets hematological malignancies and primary immune deficiencies by providing a polyclonal and safe immune response, enhanced through gene therapy and targeted conditioning.